Share This:
https://ntp.niehs.nih.gov/go/15401

TDMS Study 96020-01 Pathology Tables

NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT18
Study Type: CHRONIC                                  WITH AVERAGE SEVERITY GRADES[b]                              Date: 03/03/04
Route: GAVAGE                                  TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                   Time: 13:12:16

                                                     14 WEEK SSAC FINAL #1




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  TEFBINARYMIX

       Lock Date:  03/27/02

       Cage Range:  All

       Reasons For Removal:    25017 Scheduled Sacrifice

       Removal Date Range:     12/16/98 - 12/17/98

       Treatment Groups:       Include 001    0 NG /  0 UG
                               Include 004    300 NG /100 UG
                               Include 005    300 NG /300 UG
                               Include 006    300 NG /3000 UG






























a  Number of animals examined microscopically at site and number of animals with lesion
b  Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

                                                              Page   1


NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT18  
Study Type: CHRONIC                                  WITH AVERAGE SEVERITY GRADES[b]                              Date: 03/03/04    
Route: GAVAGE                                  TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                   Time: 13:12:16    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                   0 NG /       300 NG /     300 NG /     300 NG /                               
                                                      0 UG         100 UG       300 UG       3000 UG                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially In Study                          98           80           98           80                                     
                                                                                                                                    
  Scheduled Sacrifice                                 16           10           16           10                                     
  Early Deaths                                                                                                                      
  Survivors                                                                                                                         
                                                                                                                                    
  Animals Examined Microscopically                    10           10           10           10                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (10)         (10)         (10)         (10)                                   
      Fatty Change, Diffuse                                                      1 [1.0]      8 [1.6]                               
      Inflammation                                    10 [1.0]     10 [1.0]     10 [1.0]     10 [1.1]                               
      Mixed Cell Focus                                              1                                                               
      Pigmentation                                                  7 [1.0]      5 [1.0]      5 [1.0]                               
      Hepatocyte, Hypertrophy                                       3 [1.0]      6 [1.0]     10 [2.0]                               
   Pancreas                                           (10)         (10)         (10)         (10)                                   
      Basophilic Focus                                                           2            1                                     
      Acinus, Atrophy                                               1 [1.0]                   1 [1.0]                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (10)         (10)         (10)         (10)                                   
      Hypertrophy                                                                1 [1.0]      3 [1.3]                               
   Thyroid Gland                                      (10)         (10)         (10)         (10)                                   
      Follicular Cell, Hypertrophy                     3 [1.0]      6 [1.0]      8 [1.4]      6 [1.0]                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Average severity grade (1-minimal;2-mild;3-moderate;4-marked)                                                                    
                                                                                                                                    
                                                             Page    2                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT18  
Study Type: CHRONIC                                  WITH AVERAGE SEVERITY GRADES[b]                              Date: 03/03/04    
Route: GAVAGE                                  TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                   Time: 13:12:16    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                   0 NG /       300 NG /     300 NG /     300 NG /                               
                                                      0 UG         100 UG       300 UG       3000 UG                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
GENITAL SYSTEM - CONT                                                                                                               
   Ovary                                              (10)         (10)         (10)         (10)                                   
      Atrophy                                          4 [3.3]      1 [4.0]      3 [3.7]      4 [3.5]                               
   Uterus                                             (10)         (10)         (10)         (10)                                   
      Metaplasia, Squamous                             2 [1.0]      1 [1.0]      1 [1.0]      3 [1.0]                               
      Endometrium, Hyperplasia, Cystic                                                        1 [3.0]                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Spleen                                             (10)                                   (10)                                   
      Pigmentation                                    10 [1.1]                               10 [1.0]                               
   Thymus                                             (10)         (10)         (10)         (10)                                   
      Atrophy                                                                    1 [2.0]      3 [1.0]                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (10)         (10)         (10)         (10)                                   
      Hemorrhage                                                                 1 [1.0]                                            
      Inflammation                                                               1 [1.0]      2 [1.0]                               
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Average severity grade (1-minimal;2-mild;3-moderate;4-marked)                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page    3                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT18  
Study Type: CHRONIC                                  WITH AVERAGE SEVERITY GRADES[b]                              Date: 03/03/04    
Route: GAVAGE                                  TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                   Time: 13:12:16    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                   0 NG /       300 NG /     300 NG /     300 NG /                               
                                                      0 UG         100 UG       300 UG       3000 UG                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Average severity grade (1-minimal;2-mild;3-moderate;4-marked)                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page    4                                                              
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------